Clinical Trials Logo

ARDS, Human clinical trials

View clinical trials related to ARDS, Human.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04629105 Active, not recruiting - Covid19 Clinical Trials

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

RECOVER
Start date: July 24, 2020
Phase: Phase 1
Study type: Interventional

A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV coronavirus infection, or resultant from influenza virus infection.

NCT ID: NCT04605133 Active, not recruiting - ARDS, Human Clinical Trials

Electrical Impedance Tomography Monitoring and Invasive Mechanical Ventilation During Pronation in Acute Respiratory Distress Syndrome.

Start date: June 1, 2020
Phase:
Study type: Observational

Acute respiratory distress syndrome is an acute form of lung injury. The most commonly used classification criteria for this syndrome are Berlin's Criteria. The actual literature underlines the advantages of prone position in mild or severe forms of ARDS in association with invasive mechanical ventilation. The hypothesis of this study is to investigate the effective ventilation and perfusion modifications during pronation assessed with clinical parameters and with the aid of the electrical impedance tomography.

NCT ID: NCT04456361 Active, not recruiting - Covid-19 Clinical Trials

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

Start date: April 16, 2020
Phase: Early Phase 1
Study type: Interventional

This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days post-treatment.

NCT ID: NCT04447833 Active, not recruiting - COVID Clinical Trials

Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome

ARDS-MSC-205
Start date: June 17, 2020
Phase: Phase 1
Study type: Interventional

This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.

NCT ID: NCT04382391 Active, not recruiting - Respiratory Failure Clinical Trials

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

SAVIORII
Start date: May 8, 2020
Phase: N/A
Study type: Interventional

The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care (active) vs. standard of care alone (SoC), the control group. The gammaCore® (nVNS) treatments will be used acutely and prophylactically. The aims of this study are to summarize and compare the incidence of clinical events and pro-inflammatory cytokine levels in patients randomized to use of gammaCore Sapphire plus standard of care vs standard of care alone in patients hospitalized for CoViD-19. Secondary objectives are demonstrate the safety of gammaCore Sapphire use in patients hospitalized for CoViD-19.

NCT ID: NCT04354220 Active, not recruiting - Critical Illness Clinical Trials

Capnography Monitoring in Ventilated Children

Start date: June 9, 2020
Phase:
Study type: Observational

End-tidal CO2 measurements in children will be assessed for their accuracy with arterial CO2 measurements.